Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFBA |
Texto Completo: | http://www.repositorio.ufba.br/ri/handle/ri/5515 |
Resumo: | texto completo: acesso restrito; p.391–398. |
id |
UFBA-2_7b7fce514bcc87b2403a5772a5989317 |
---|---|
oai_identifier_str |
oai:repositorio.ufba.br:ri/5515 |
network_acronym_str |
UFBA-2 |
network_name_str |
Repositório Institucional da UFBA |
repository_id_str |
1932 |
spelling |
Louzã, Mário RodriguesElkis, HelioRuschel, SandraOliveira, Irismar Reis deBressan, Rodrigo AffonsecaAbreu, Paulo Belmonte deGrabowski, HamiltonAppolinário, José CarlosLouzã, Mário RodriguesElkis, HelioRuschel, SandraOliveira, Irismar Reis deBressan, Rodrigo AffonsecaAbreu, Paulo Belmonte deGrabowski, HamiltonAppolinário, José Carlos2012-03-06T19:56:21Z20111178-2021http://www.repositorio.ufba.br/ri/handle/ri/5515v. 7.texto completo: acesso restrito; p.391–398.Background: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication. Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score. Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well- tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%). Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2012-03-06T19:56:21Z No. of bitstreams: 1 NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf: 205337 bytes, checksum: baebc6dbfffd4b121be24a2b22102c8f (MD5)Made available in DSpace on 2012-03-06T19:56:21Z (GMT). No. of bitstreams: 1 NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf: 205337 bytes, checksum: baebc6dbfffd4b121be24a2b22102c8f (MD5) Previous issue date: 2011http://dx.doi.org/10.2147/NDT.S20589reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBApatient complianceadherencerisperidonedelayed-action preparationsschizophreniaLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophreniaNeuropsychiatric Disease and Treatmentinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01enginfo:eu-repo/semantics/openAccessORIGINALNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdfNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdfapplication/pdf205337https://repositorio.ufba.br/bitstream/ri/5515/1/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdfbaebc6dbfffd4b121be24a2b22102c8fMD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/5515/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXTNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txtNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txtExtracted texttext/plain36768https://repositorio.ufba.br/bitstream/ri/5515/3/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txt6008e0e8f91b5cd6d662099ecd1c2f3bMD53ri/55152022-07-05 14:02:49.301oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:02:49Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false |
dc.title.pt_BR.fl_str_mv |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
dc.title.alternative.pt_BR.fl_str_mv |
Neuropsychiatric Disease and Treatment |
title |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
spellingShingle |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia Louzã, Mário Rodrigues patient compliance adherence risperidone delayed-action preparations schizophrenia |
title_short |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_full |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_fullStr |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_full_unstemmed |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_sort |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
author |
Louzã, Mário Rodrigues |
author_facet |
Louzã, Mário Rodrigues Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Abreu, Paulo Belmonte de Grabowski, Hamilton Appolinário, José Carlos |
author_role |
author |
author2 |
Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Abreu, Paulo Belmonte de Grabowski, Hamilton Appolinário, José Carlos |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Louzã, Mário Rodrigues Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Abreu, Paulo Belmonte de Grabowski, Hamilton Appolinário, José Carlos Louzã, Mário Rodrigues Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Abreu, Paulo Belmonte de Grabowski, Hamilton Appolinário, José Carlos |
dc.subject.por.fl_str_mv |
patient compliance adherence risperidone delayed-action preparations schizophrenia |
topic |
patient compliance adherence risperidone delayed-action preparations schizophrenia |
description |
texto completo: acesso restrito; p.391–398. |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011 |
dc.date.accessioned.fl_str_mv |
2012-03-06T19:56:21Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufba.br/ri/handle/ri/5515 |
dc.identifier.issn.none.fl_str_mv |
1178-2021 |
dc.identifier.number.pt_BR.fl_str_mv |
v. 7. |
identifier_str_mv |
1178-2021 v. 7. |
url |
http://www.repositorio.ufba.br/ri/handle/ri/5515 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.pt_BR.fl_str_mv |
http://dx.doi.org/10.2147/NDT.S20589 |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFBA instname:Universidade Federal da Bahia (UFBA) instacron:UFBA |
instname_str |
Universidade Federal da Bahia (UFBA) |
instacron_str |
UFBA |
institution |
UFBA |
reponame_str |
Repositório Institucional da UFBA |
collection |
Repositório Institucional da UFBA |
bitstream.url.fl_str_mv |
https://repositorio.ufba.br/bitstream/ri/5515/1/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf https://repositorio.ufba.br/bitstream/ri/5515/2/license.txt https://repositorio.ufba.br/bitstream/ri/5515/3/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txt |
bitstream.checksum.fl_str_mv |
baebc6dbfffd4b121be24a2b22102c8f 1b89a9a0548218172d7c829f87a0eab9 6008e0e8f91b5cd6d662099ecd1c2f3b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA) |
repository.mail.fl_str_mv |
|
_version_ |
1808459395517906944 |